Attribution must evolve alongside the patient

Over the past decade, Medicare Advantage plans have built an ecosystem of specialty value-based programs — oncology, kidney care, cardiovascular, post-acute, and more. Each is designed around a simple premise: when one disease drives cost, a specialized partner can manage it better.

That logic works, but only up to a point.

Today, plans are running into a structural limitation: their sickest, highest-cost patients no longer fit cleanly into any single program. These patients don’t stay “complex chronic” forever. They progress. And as they do, the dominant driver of cost shifts from a single disease to serious illness itself.

Yet, most often, program attribution doesn’t shift alongside them.

Where the current model breaks

To maintain accountability across programs, plans rely on “carve-outs”, meaning they assign each patient to a single program to avoid overlap.

Operationally, this makes sense. Clinically, it breaks down.

Take a patient with metastatic cancer and heart failure. Early on, attributing the patient to an oncology program and carving them out of other programs is appropriate. Cancer-specific treatment decisions, complications, and disease progression require expertise in cancer care.

As the patient declines, however, the drivers of utilization change. Hospitalizations are no longer driven by chemotherapy, but infections, frailty, heart failure, and caregiver strain. At this stage, the overall condition of serious illness becomes the primary driver of cost.

This patient is no longer just a “cancer patient”. They have become a seriously ill patient who happens to have cancer, heart disease, and other conditions. In this instance, however, most plans would keep cancer atop the attribution hierarchy, and the patient would continue to be managed through a disease-specific lens.

A necessary shift: recognizing serious illness as the primary condition

Disease-based attribution works for complex chronic patients but it breaks down once patients become seriously ill. At that stage, care is no longer about optimizing a disease. It is about managing the patient:

• coordinating across multiple conditions
• stabilizing the patient and supporting the caregiver
• alleviating symptom burden and preventing avoidable hospitalizations
• navigating end-of-life decisions

Serious illness is not just the progression of individual diseases. It functions as a distinct clinical state with its own drivers of cost and utilization. That is why when a patient reaches this stage, attribution should shift to a serious illness manager. Not because cancer, heart disease, or kidney disease disappear, but because they are no longer the primary problem.

Why this gap has persisted — until now

Historically, even when serious illness became the dominant clinical issue, plans had no viable alternative. There was no entity designed to:

• take ownership of the patient across conditions
• manage serious illness longitudinally
• be held accountable for total cost of care in the final year of life

So patients remained in disease-specific programs by default. Not because it was right, but because there was nowhere else to assign responsibility.

This was a structural limitation, not a strategic choice. That constraint is now changing.

A new category of care — serious illness management — has emerged, designed specifically for this stage of patient need. Organizations like Empassion provide, for the first time, a clear program for these patients to go when serious illness becomes the dominant condition.

Placing accountability where it belongs

Plans are right to insist on a single accountable entity. At the same time, it is in the best interest of the patient and the plan for attribution to reflect the patient’s primary clinical reality.

So the question plans should be asking is not: “Should there be one owner?” but rather “What is the primary condition driving this patient’s care right now and who is best equipped to manage it?” For seriously ill patients, the answer is increasingly clear: that is not a disease-specific program. 

In practice, that means plans must:

• assign patients to disease-based programs when a single condition dominates
• transition patients when serious illness becomes the primary clinical issue
• enable coordination across programs during that transition

The goal is thus not to eliminate specialty programs, but rather to appropriately align them to the patient’s stage of illness.

The bottom line

As plans look to manage their highest-cost patients, the biggest challenge — and the biggest opportunity — lies in the logic of patient attribution and the execution of great handoffs.

For years, seriously ill patients have remained in disease-based programs. Not because it worked, but because there was nowhere else to assign accountability. That is changing now.Serious illness is a distinct clinical state and requires specialized expertise to manage well. Getting this right is the difference between fragmented care with high, unnecessary utilization and care that is coordinated, humane, and aligned to what patients actually need in the most vulnerable stage of their lives.